Finance

Lists
2269:HKG
WuXi Biologics (Cayman) Inc
HK$ ४८.२०
-०.९०%
(-०.४४) 1D
अक्टोबर १६, १६:०८:१४ GMT+८  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2269...
Open
HK$ ४९.९८
High
HK$ ५०.८५
Low
HK$ ४५.८२
Mkt. cap
१.९८ खरब
Avg. vol.
३.०४ करोड
Volume
५.५२ करोड
P/E ratio
३४.४८
52-wk high
HK$ ५८.००
52-wk low
HK$ २८.४८
EPS
HK$ १.४०
Shares outstanding
१.२३ अरब
No. of employees
१५ हजार
Open
HK$ ४९.९८
High
HK$ ५०.८५
Low
HK$ ४५.८२
Mkt. cap
१.९८ खरब
Avg. vol.
३.०४ करोड
Volume
५.५२ करोड
P/E ratio
३४.४८
52-wk high
HK$ ५८.००
52-wk low
HK$ २८.४८
EPS
HK$ १.४०
Shares outstanding
१.२३ अरब
No. of employees
१५ हजार
News stories
From web sources and news partners
MarketBeat
MarketBeat
·
१९ मिनेट पहिले
APA (NASDAQ:APA) Sets New 1-Year High - Time to Buy?
TradingView
TradingView
·
३६ मिनेट पहिले
S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
RealMoney Pro
RealMoney Pro
·
३७ मिनेट पहिले
Charting the Markets: The S&P Is Still Bullish. But for How Long?
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc
CEOZhisheng Chen
Employees१४.७ हजार
Founded२०१०
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
५.९२ अरब
५.९२ अरब
५.८९ अरब
५.८९ अरब
Cost of goods sold
३.०४ अरब
३.०४ अरब
३.१७ अरब
३.१७ अरब
Cost of revenue
३.०४ अरब
३.०४ अरब
३.१७ अरब
३.१७ अरब
Research and development expenses
२५.४९ करोड
२५.४९ करोड
२१.५१ करोड
२१.५१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६३.१० करोड
६३.१० करोड
५९.१६ करोड
५९.१६ करोड
Operating expense
९२.१७ करोड
९२.१७ करोड
८६.०१ करोड
८६.०१ करोड
Total operating expenses
३.९६ अरब
३.९६ अरब
४.०३ अरब
४.०३ अरब
Operating income
१.९६ अरब
१.९६ अरब
१.८६ अरब
१.८६ अरब
Other non operating income
३.३६ करोड
३.३६ करोड
४.२२ करोड
४.२२ करोड
EBT including unusual items
१.९६ अरब
१.९६ अरब
१.७१ अरब
१.७१ अरब
EBT excluding unusual items
१.९४ अरब
१.९४ अरब
१.७० अरब
१.७० अरब
Income tax expense
४७.६१ करोड
४७.६१ करोड
२५.१५ करोड
२५.१५ करोड
Effective tax rate
२४.२४%
२४.२४%
१४.७१%
१४.७१%
Other operating expenses
-
-
-
-
Net income
१.२८ अरब
१.२८ अरब
१.२२ अरब
१.२२ अरब
Net profit margin
२१.७०%
२१.७०%
२०.७०%
२०.७०%
Earnings per share
-
-
-
-
Interest and investment income
११.५३ करोड
११.५३ करोड
१०.६४ करोड
१०.६४ करोड
Interest expense
-२.९८ करोड
-२.९८ करोड
-२.२३ करोड
-२.२३ करोड
Net interest expenses
८.५५ करोड
८.५५ करोड
८.४१ करोड
८.४१ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
२.२४ अरब
२.२४ अरब
२.२७ अरब
२.२७ अरब
Gain or loss from assets sale
३१.७३ करोड
३१.७३ करोड
-
-
AI content may include mistakes. Learn more
Google एपहरू